English
Home > Products > CAS NO 14898-67-0

China CAS NO 14898-67-0 Factory

We emphasize advancement and introduce new products and solutions into the market each year for CAS NO 14898-67-0,14898-67-0,Ruthenium(III) chloride hydrate(1:x), We look ahead to receiving your enquires quickly and hope to have the chance to get the job done together with you inside the future. Welcome to get a seem at our organization.
CAS NO 14898-67-0, Over the years, with high-quality solutions, first- class service, ultra-low prices we win thee trust and favor of customers. Nowadays our products sell all over the domestic and abroad. Thanks for the regular and new customers support. We offer high quality product and competitive price, welcome the regular and new customers cooperate with us!

Related Products

Hot Products

  • 9-Dehydroandrostenedione

    9-Dehydroandrostenedione

    Product Name:9-Dehydroandrostenedione
    Molecular Formula:C19H24O2
    Molecular Weight:284.39
    CAS Registry Number:1035-69-4
  • 5-(Bromomethyl)-4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine

    5-(Bromomethyl)-4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine

    Product Name:5-(Bromomethyl)-4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidine
    Molecular Formula:C16H19BrFN3O2S
    Molecular Weight:416.31
    CAS Registry Number:799842-07-2
  • BOC-L-Serine

    BOC-L-Serine

    Product Name:BOC-L-Serine
    Molecular Formula:C8H15NO5
    Molecular Weight:205.21
    CAS Registry Number:3262-72-4
  • Salidroside

    Salidroside

    Product Name:Salidroside
    Molecular Formula:C14H20O7
    Molecular Weight:300.3
    CAS Registry Number:10338-51-9
  • FMOC-Arg(Pbf)-OH

    FMOC-Arg(Pbf)-OH

    Product Name:FMOC-Arg(Pbf)-OH
    Molecular Formula:C34H40N4O7S
    Molecular Weight:648.77
    CAS Registry Number:154445-77-9
  • Rilmenidine phosphate

    Rilmenidine phosphate

    Product Name:Rilmenidine phosphate
    Molecular Formula:C10H19N2O5P
    Molecular Weight;278.24
    CAS Registry Number;85409-38-7
  • Related Blog
  • Reviews

  • Baloxavir marboxil

    Baloxavir marboxil is used to treat flu symptoms caused by influenza virus in people who have had symptoms for no more than 48 hours. Baloxavir marboxil will not treat the common cold. Baloxavir marboxil is for adults and children who are at least 12 years old and weigh at least 88 pounds (40 kilograms).

  • Gilteritinib Fumarate

    Sandoo Pharmaceutica is a professional pharmaceutical intermediates manufacturer. We provide good quality Gilteritinib Fumarate Cas: 1254053-43-4. Welcome and we look forward to your inquiry!

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • CAS No. 144689-24-7 Olmesartan Introduction

    Olmesartan is an angiotensin II receptor blocker, widely used for the treatment of hypertension. The Renin-Angiotensin-Aldosterone System (RAAS) plays an importent role in the development and progression of many diseases such as hypertension...

  • Caffeine CAS No.58-08-2

    Caffeine (CAS No.58-08-2) is a xanthine alkaloid compound, a central nervous stimulant that temporarily drives away drowsiness and restores energy, and is used clinically to treat neurosis and coma recovery. Caffeinated coffee, tea, soft drinks and energy drinks are very popular, so caffeine is also the most commonly used psychotropic drug in the world.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept